| Recruiting | Study of ALK-001 on the Progression of Stargardt Disease NCT07419334 | Alkeus Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration NCT07266584 | Science Corporation | N/A |
| Recruiting | A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults NCT07425574 | Astellas Pharma Global Development, Inc. | — |
| Recruiting | Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherit NCT07502664 | Ray Therapeutics, Inc. | — |
| Recruiting | Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in NCT07439887 | Ray Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Wide Field OCTA in Ocular Diseases NCT07298174 | IRCCS San Raffaele | — |
| Recruiting | A Study of DC6001 Tablet in Healthy Chinese Adult Subjects NCT07417566 | Heronova Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations NCT07265895 | IRCCS San Raffaele | — |
| Not Yet Recruiting | Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's D NCT06989658 | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | N/A |
| Recruiting | A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) NCT07161544 | AAVantgarde Bio Srl | Phase 1 / Phase 2 |
| Recruiting | The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration NCT06319872 | University of Rochester | Phase 1 |
| Recruiting | A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Prelimina NCT06942572 | Splice Bio | Phase 1 / Phase 2 |
| Recruiting | A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT NCT06805474 | Nanoscope Therapeutics Inc. | — |
| Recruiting | Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) NCT06445322 | Ascidian Therapeutics, Inc | — |
| Recruiting | Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) NCT06467344 | Ascidian Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | An Observational Study in Children and Adults With Stargardt Disease NCT06591806 | AAVantgarde Bio Srl | — |
| Recruiting | Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retin NCT06375239 | Ray Therapeutics, Inc. | — |
| Recruiting | An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi- NCT06435000 | Splice Bio | — |
| Active Not Recruiting | Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study NCT06048185 | Nanoscope Therapeutics Inc. | — |
| Active Not Recruiting | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease NCT05956626 | Ocugen | Phase 2 / Phase 3 |
| Active Not Recruiting | Function and Imaging Assessments for G1961E-associated Stargardt Disease NCT05674058 | University Hospital, Basel, Switzerland | — |
| Completed | Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargar NCT05417126 | Nanoscope Therapeutics Inc. | Phase 2 |
| Completed | ABCA4-associated Disease in Childhood and Adolescence - a Phenotype Study NCT06377150 | University Hospital Tuebingen | — |
| Completed | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlare NCT05266014 | RBP4 Pty Ltd | Phase 1 / Phase 2 |
| Recruiting | Oral Metformin for Treatment of ABCA4 Retinopathy NCT04545736 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) NCT04239625 | Alkeus Pharmaceuticals, Inc. | Phase 2 |
| Completed | Safety and Efficacy of Emixustat in Stargardt Disease NCT03772665 | Kubota Vision Inc. | Phase 3 |
| Completed | The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies NCT05904444 | Aier Eye Hospital, Guangzhou | N/A |
| Completed | Pupil Dynamics and Color Vision for the Detection of Eye Diseases NCT04909398 | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | N/A |
| Terminated | Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy NCT02875704 | Johns Hopkins University | — |
| Completed | Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disea NCT03033108 | Kubota Vision Inc. | Phase 2 |
| Recruiting | Stem Cell Ophthalmology Treatment Study II NCT03011541 | MD Stem Cells | N/A |
| Enrolling By Invitation | Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease NCT02402660 | Alkeus Pharmaceuticals, Inc. | Phase 2 |
| Completed | The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular NCT02410122 | Johns Hopkins University | — |
| Recruiting | Inherited Retinal Degenerative Disease Registry NCT02435940 | Foundation Fighting Blindness | — |
| Completed | Phase 1 Safety Study of ALK-001 in Healthy Volunteers NCT02230228 | Alkeus Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies NCT01977846 | Foundation Fighting Blindness | — |
| Completed | Efficacy of Acupuncture in Macular Diseases NCT02255981 | Escuela Neijing | N/A |
| Terminated | Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease NCT01676766 | University of Michigan | — |